Eyeworld

INDICATIONS AND USAGE FLAREX ® ( uorometholone acetate ophthalmic suspension) is indicated for use in the treatment of steroid-responsive in ammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the eye. IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS Contraindicated in acute super cial herpes simplex keratitis, vaccinia, varicella, and most other viral diseases of the cornea and conjunctiva; mycobacterial infection of the eye; fungal diseases; acute purulent untreated infections, which like other diseases caused by microorganisms, may be masked or enhanced by the presence of the steroid; and in those persons who have known hypersensitivity to any component of this preparation. Please see brief summary of Full Prescribing Information on the adjacent page. a STUDY DESIGN: The ef cacy and safety of FLAREX (n=41) vs FML* (n=37) were evaluated in a randomized, double-blind clinical trial in 78 patients with ocular surface in ammation (eg, conjunctivitis, episcleritis, scleritis) in one or both eyes. In a separate randomized, double-blind clinical trial in 82 patients with ocular surface in ammation in one or both eyes, the ef cacy and safety of FLAREX (n=37) vs prednisolone acetate 1.0% (n=45) were evaluated. In these studies, patients administered either FLAREX or FML*/prednisolone acetate 1.0% every 2 hours for the rst 2 days and then every 4 hours thereafter, with signs and symptoms of in ammation assessed at Days 1, 3, 8, and 13. At each visit, investigators determined if symptoms in the involved eye were resolved (cured), improved, unchanged, or worsened. If a patient was rated as cured before the end of the study, steroid drops were discontinued and the patient was considered to have completed the trial. 2 b Cost information based on Wholesale Acquisition Cost (WAC), 2019 data. © 2019 Eyevance Pharmaceuticals LLC. All rights reserved. FLAREX ® is a registered trademark of Alcon Research, Ltd. *All other trademarks are the property of their respective owners. FLA-09-19-AD-40 PRECISION POTENCY FLAREX ® provides the precise level of potency when treating ocular surface inflammation 1,2 By balancing ef cacy and safety, you can tailor treatment to meet the exact needs of your patients 1 • Superior ef cacy vs FML ® ( uorometholone ophthalmic suspension, USP) 0.1%* 2,a • Similar ef cacy to prednisolone acetate 1.0% 2,a • No differences in adverse reactions vs FML* and prednisolone acetate 1.0% 2,a • The lowest-cost branded corticosteroid 3,b • No generic equivalent—prescribe FLAREX by name 4 Learn more at MyFlarex.com treatment to meet the exact needs of your patients 1

• Blank Page
• Blank Page (1)